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Pylephlebitis and acute mesenteric ischemia in a
young man with inherited thrombophilia and
suspected foodborne illness
Sarah P. Pradka, MD,a Christine T. Trankiem, MD,b and John J. Ricotta, MD,a Washington, DC
We report on a young man who developed complicated pylephlebitis after foodborne illness. Despite antibiotics and
resection of the focus of infectious colitis, he developed extensive small bowel infarction. He was treated with
anticoagulation, local thrombolytic infusion, and resection of irreversibly ischemic small bowel. Thrombophilia workup
demonstrated heterozygosity for factor V Leiden and the prothrombin G20210A mutation. The complications of
pylephlebitis can be minimized by using systemic anticoagulation, thrombectomy, and/or local thrombolytic infusion
along with antibiotics and surgical management of the infection. Evaluation for thrombophilic states should be
considered, particularly if a patient does not respond to initial therapy. (J Vasc Surg 2012;55:1769-72.)
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bPylephlebitis, or thrombophlebitis of the portal vein, is
a potentially devastating complication of intra-abdominal
infection. Antibiotics and resection of the focus of infection
may not be sufficient to control thrombus progression,
particularly in patients with thrombophilic disorders or late
presentation.
CASE REPORT
An otherwise healthy 27-year-old man presented to an outside
hospital with a 6-day history of gastrointestinal complaints after
eating a spoiled casserole from a carry-out restaurant. His symp-
toms began with vomiting and watery diarrhea, followed by obsti-
pation and right lower quadrant pain.
Computed tomography (CT) of the abdomen at the outside
hospital was initially consistent with right-sided colitis. He was
treated for presumptive infectious colitis with levofloxacin and
metronidazole, but within 48 hours, his abdominal pain worsened
and he developed pancreatitis (lipase 1000). Seventy-two hours
after presentation, the final interpretation of his abdominal CT
identified nonocclusive intrahepatic portal vein thrombosis and
hypoperfusion of the right lobe of the liver. Repeat CT that day
showed interval occlusive thrombus of the superiormesenteric vein
(SMV) (Figs 1 and 2). He was then transferred to our center.
On arrival, he was hemodynamically stable with mild diffuse
abdominal tenderness. A heparin infusion was started and antibi-
otics were continued (piperacillin/tazobactam and metronida-
zole). Colonoscopy that day demonstrated congested, ulcerated
colonic mucosa and a 4-cm inflammatory mass in the proximal
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doi:10.1016/j.jvs.2011.12.055scending colon (Fig 3). The patient was then taken to the oper-
ting room to resect the infectious focus that was believed to have
recipitated the portomesenteric thrombus; a right hemicolec-
omy was performed. Anticoagulation was held briefly for surgery
nd resumed 2 hours postoperatively. Blood and peritoneal fluid
ultures were negative but Yersinia pseudotuberculosis colitis was
linically suspected based on history and tissue pathology.1 His
tool tested negative for Clostridium dificile by enzyme-linked
mmunosorbent assay.
Ten hours postoperatively (hospital day 5), the patient devel-
ped frank peritonitis and shock (pH 7.23, base excess8.4). The
eparin infusion was held briefly for emergent re-exploration. The
mall bowel was deep purple 25 cm proximal to the ileocolonic
nastomosis but potentially viable. The veins of the small bowel
esentery were engorged, and there was no antimesenteric Dopp-
er signal. Our assessment was that the portomesenteric thrombus
ad propagated to the point of restricting small bowel perfusion.
he patient went directly to interventional radiology for thrombo-
ytic infusion and heparin was resumed 1 hour postoperatively.
Angiogram demonstrated an occluded SMV and slow flow in
he superior mesenteric artery (SMA). Tissue plasminogen activa-
or (TPA) infusion (1 mg/h) was started via a SMA catheter.
ithin 2 hours, however, his shock worsened, and dusky, edema-
ous bowel was visible under the clear open abdominal dressing. A
tat echocardiogram was consistent with acute pulmonary embo-
ism (PE). The source of PE was suspected to be a femoral venous
ine, which was removed. He returned to the operating room
mergently for peritonitis. A 112-cm segment of small bowel
roximal to the ileocolonic anastomosis was grossly ischemic with
o Doppler signal; this was resected. The heparin drip resumed 1
our later, but TPA was discontinued. The next day, the patient
nderwent attempted placement of a thrombolytic catheter into
he SMV by internal jugular approach, but the portal venous
ystem could not be accessed. Heparin infusion was continued
uring all subsequent surgeries, which included a final resection of
0 cm of infarcted small bowel and eventual ileostomy.
An inherited thrombophilia was suspected in this patient,
lthough he denied a personal or family history of venous throm-
oembolism (Table). He was found to be heterozygous for the
actor V Leiden and prothrombin II mutations. Functional assays
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June 20121770 Pradka et alof antithrombin III and proteins S and C demonstrated decreased
activity, most likely due to factor consumption. Resistance to
heparin was not suspected because thromboelastography showed
appropriate correction with heparinase. He is a carrier of the
methylenetatrahydrofolate reductase C677T polymorphism, but
Fig 1. CT prior to transfer to our center demonstrated intrahe-
patic portal vein thrombosis and portal venous air (arrow), accom-
panied by hypoperfusion of the right liver.
Fig 2. CT repeated on the date of transfer to our center demon-
strated ongoing inflammatory changes in the ascending colon
(short arrow) and interval development of thrombus in the superior
mesenteric vein (long arrow).homocysteine level was confirmed to be normal. eThe patient was eventually transitioned to anticoagulation
ith warfarin, which will continue indefinitely. Nine months after
is initial illness, his portal vein was radiographically patent, and his
stomy was reversed. He is now doing well.
ISCUSSION
Pylephlebitis should be treated aggressively and com-
rehensively with the objective of avoiding visceral isch-
mia, liver abscess, and chronic portal hypertension. Anti-
iotics are essential because uncontrolled infection, not
isceral ischemia, is the primary threat to the patient’s life.2
lood cultures should be obtained and broad-spectrum
ntibiotics started for any patient with acute portal vein
hrombosis (PVT) and fever, regardless of whether an
ntra-abdominal infection has been identified. Cultures are
requently polymicrobial, but Bacteroides fragilis is most
ommon and has unique prothrombotic effects.3-5 Antibi-
tics should continue for at least 4 weeks to cover early
adiographically occult hepatic abscesses.2 Surgical resec-
ion of the primary infection should be considered in pa-
ients who are stable enough for surgery.6-8 An open
hrombectomy can be performed during the laparotomy.
Advances in genetic testing have demonstrated that
oncirrhotic, nonmalignant portal vein thrombosis is fre-
uently the result of an inherited thrombophilia superim-
osed on local risk factors such as infection, inflammatory
owel disease, or trauma. Among 100 case reports of
ylephlebitis since 1971, approximately one-third of the
atients who were screened for genetic thrombophilia were
ound to have an abnormality.9 Another series of 92 pa-
ients with acute PVT demonstrated a relative risk of 2.7 in
atients with factor V Leiden mutation, 1.4 for prothrom-
in 20210 G/A mutation, and 4.6 for protein C defi-
iency.10 The prothrombin 20210 G/A mutation may
ccount for many PVT cases that were previously consid-
ig 3. Colonoscopy was performed on transfer to our center (hos-
ital day 4) and demonstrated congested, ulcerated colonic mucosa
nd an inflammatory mass in the proximal ascending colon (arrow).red idiopathic.11
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Volume 55, Number 6 Pradka et al 1771Thrombolytic agents may be particularly helpful in
cases of hypercoagulable states and/or extensive thrombus.
Hollingshead et al report complete portal vein recanaliza-
tion in 15% and partial recanalization in 60% of portal vein
thromboses treated with thrombolysis via SMA or transhe-
patic puncture.12 Lytic therapy is most effective in the early
stages of bowel ischemia and should be avoided in severely
ischemic or infarcted bowel. A catheter can be introduced
directly into the portal venous system by a percutaneous
transhepatic or a transjugular-intrahepatic approach, but
this provides poor delivery to the small splanchnic veins.
Infusion into the SMA reaches the small splanchnic veins and
carries less risk of intra-abdominal hemorrhage, but it requires
more time to resolve the clot.13,14 There are also anecdotal
reports of placement of a lytic catheter directly into a jejeunal
vein at the time of laparotomy.15
Anticoagulation has traditionally been reserved for
cases of pylephlebitis that are complicated by mesenteric
vein thrombosis, hypercoagulable state, and progression of
thrombus.16,17 More recently, however, indications have
expanded due to a low incidence of bleeding, weighed
against the significant morbidity of chronic portal hyper-
tension.18 Duffy et al recommend anticoagulation for pa-
tients with fever despite surgery and/or antibiotics, after
resection for pylephlebitis-related ischemia, and for “exten-
sive acute pylethrombosis” on imaging or exploration.8
Sherigar et al recommend that anticoagulation and/or
thrombolysis be considered for all cases of pylephebitis.19 A
review of 100 pylephlebitis cases showed superior recanali-
zation (26% vs 15%) and decreased mortality (6% vs 22%)
among patients receiving anticoagulation.9 Anticoagula-
tion may also reduce septic embolization to the liver.2 In
patients who require bowel resection, anticoagulation is
associated with a survival benefit over surgery alone.20
Anticoagulation should be held briefly if ever for surgery.
As with other forms of PVT, pylephlebitis is generally
treated with a 3- to 6-month course of anticoagulation,
which may be extended in the presence of noncorrectable
prothrombotic risk factors and/or thrombus extension to
Table. Thrombophilia screening in our patient
Laboratory test Result
Factor V Leiden mutation Genotype G/A
Prothrombin II G20210A mutation Genotype G/A
Antithrombin III functional assay 36% activity
Protein C functional assay 50% activity
Protein S functional assay 30% activity
Anticardiolipin antibody IgG 7 GPL units/mL
Anticardiolipin antibody IgM 2 MPL units/mL
Homocysteine 3 mol/L
Methylenetatrahydrofolate reductase
(MTHFR) C677T mutation
Genotype C/T
Methylenetatrahydrofolate reductase
(MTHFR) A1298C mutation
Genotype A/A
JAK2 V617F mutation Negativethe mesenteric veins.3ONCLUSIONS
This case demonstrates the importance of early treat-
ent for pylephlebitis, to treat the hematologic and infec-
ious pathology. Anticoagulation should be considered for
ll patients to facilitate recanalization of the portal vein,
ven if bowel ischemia is not suspected. Earlier and more
ggressive anticoagulation may have avoided bowel infarc-
ion in this patient. Clinicians should also consider the
resence of a thrombophilic disorder in a patient with
typical presentation or inadequate response to treatment.
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